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Summary The tissue and cellular distribution of the DNA repair protein 06-alkylguanine-DNA-
alkyltransferase (ATase) is an important question in relation to the response of tumour and normal tissues to
chemotherapeutic regimes employing alkylating agents such as methyltriazenes and nitrosoureas. In order to
examine this issue by immunostaining, we have raised a rabbit antiserum to apparently pure recombinant
human enzyme. The antiserum is highly specific and sensitive, detecting a band at 24 kDa on western blots of
crude extracts of ATase-expressing human lymphoblastoid cells, liver and melanoma. Adjacent sections of
acetone or formalin fixed normal human liver and subcutaneous malignant melanoma were reacted with
preimmune serum or antiserum and an immunoperoxidase detection system with silver enhancement was used
to locate binding of the primary antibody to the antigen. In sections reacted with preimmune serum or with
antigen-preadsorbed antiserum, only faint cytoplasmic and little or no nuclear staining was seen. In contrast,
using antiserum, the reaction in positively staining cells was very intense and predominantly nuclear. In the
liver, there was interindividual variation in the cellular distribution of reaction with staining present in all
discernable cell types in most samples but confined to the hepatocytes and bile duct epithelial cells in others. In
the melanoma sections, all discernable cell types showed mainly nuclear staining: the intensity of staining
varied between tissue samples and there was evidence of a range of intermediate staining intensities with some
melanoma cells showing no detectable reaction.
Some antitumour alkylating agents including the methylating
agents dacarbazine (DTIC), procarbazine, temozolomide,
CB10277 and streptozotocin and the chloroethylating agents
chlorozotocin, BCNU and related nitrosoureas such as
TCNU and fotemustine exert their effects by interaction with
DNA. There is increasing evidence that one of the principal
mechanisms of cellular resistance to the cytotoxic and other
biological effects of these agents is related to the expression
of the DNA repair enzyme 06-alkylguanine-DNA-alkyl-
transferase (ATase): cultured cells or tumour xenografts that
express high levels of this enzyme either from the endogenous
or a cloned, transfected gene are generally more resistant to
the toxic effects of these agents than those expressing low
levels (D'Incalci et al., 1988; Margison & O'Connor, 1990;
Pegg, 1990). There is currently considerable interest in
measuring the amounts of ATase in tumour and normal
biopsy material (Myrnes et al., 1984; Weistler et al., 1984;
Maynard et al., 1989; Kyrtopoulos et al., 1990) and also in
peripheral lymphocytes (Sagher et al., 1988; Gerson et al.,
1988; Lee et al., 1991), which have the distinct advantage of
being more accessible and amenable to repeat sampling. The
aim of such work is to assess whether or not there is any
evidence for a similar correlation between ATase levels and
the response of the tumour, or the tissues in which toxic side
effects occur, to chemotherapeutic regimens that include these
types of agents and also to monitor the effects of various
drugs and treatment schedules on ATase activities (Gerson et
al., 1988; Lee et al., 1991).
Although ATase assay methods are extremely sensitive, the
results obtained using human tumour biopsies are always a
tissue-average measurement and take no account of cellular
heterogeneity in ATase expression This is clearly a very
critical question in relation to chemotherapeutic effectiveness
since small numbers of cells with high levels of ATase could
not only give the impression of a low overall ATase level in
tissue homogenates but also be the resistant cells that even-
tually result in tumour relapse and recurrence.
A similar question arises with respect not only to the toxic
side effects of chemotherapeutic alkylating agents but also to
the numerous adverse biological effects of environmental or
endogenously formed alkylating agents, or their precursors
(Bartsch & Montesano, 1984). In this case individual cells
that express very low levels of ATase might be expected to be
the most susceptible to these effects, which include mutation
and malignant transformation (see Margison & O'Connor,
1990). Indeed, such a situation has been observed in an
animal model system in which specific target cells for mes-
enchymal tumour induction in rats were shown to be
damaged by an environmental alkylating agent and to lack
the capacity for repair of 06-methylguanine, even over a
period of several weeks (Fan et al., 1990).
In order to address these questions, we have generated
polyclonal antibodies to the human ATase and these have
been used to visualise the enzyme in human normal and
tumour tissue. Staining was heterogeneous and almost exclus-
ively nuclear in normal liver and in subcutaneous malignant
melanoma nodules.
Materials and methods
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Antibody production
E.coli harbouring pRBShAT (see Potter et al., 1991) were
grown in LB medium containing carbenicillin (Sigma,
0.1 mg ml-') at 30°C to an E600 of 0.2 then at 42°C for 3 h
prior to harvesting by centrifugation. Crude sonicates of
these bacteria, which expressed the recombinant human pro-
tein to approximately 3% of total protein, were subjected to
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DNA cellulose affinity purification essentially as previously
described (Wilkinson et al., 1989). SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by Coomassie blue
staining showed the pooled, concentrated material to be
apparently homogeneous (estimated >95% pure). Samples
(100fg) of this were used to immunise prebled Half-lop
rabbits: the primary injection was followed by three boosts at
4-week intervals and bleeds were taken one week after each
of the boosts for preparation of serum. Dilutions for use in
western blotting and immunohistology were estimated by
ELISA.
Western blotting
Crude sonicates of the human lymphoblastoid cell lines RAJI
and TK6 were assayed for ATase activity as described (Lee
et al., 1991). These and similar extracts of human tissues (see
below) each containing 30gg of total protein were subjected
to SDS-PAGE and transferred to Hybond C (Amersham
International PLC) membranes. After blocking with non-fat
milk (5% Marvel in Tris-buffered saline (TBS)), the memb-
ranes were incubated with anti-human ATase antiserum (3rd
bleed serum diluted 1:1000 in blocking buffer) and then goat
anti-rabbit alkaline phosphatase (Dako Ltd., High Wycombe
UK). Antibody complexes were revealed by reaction with
nitro blue tetrazolium and bromochloroindolyl phosphate.
Immunohistology
Ethical committee approved human liver and melanoma tis-
sue samples were obtained by trucut needle or surgical
biopsy. Tissues were fixed in formalin or acetone and wax
embedded. Sections (3 t) were cut and mounted onto gelatin-
subbed slides, dewaxed and rehydrated. The sections were
treated with methanol and exposed overnight at 4°C to the
anti-human ATase antiserum (3rd bleed) or preimmune
serum diluted 1:1000 in PBS. As an additional control, an
aliquot of the diluted immune serum was preincubated with
the pure recombinant human ATase at 4°C overnight prior
to use in the above procedure. The sections were then
incubated with swine anti-rabbit antibody (SAR, (Dako)
diluted 1:40 in PBS containing 10% normal rat serum) for
45 min at room temperature, washed in PBS and incubated
with rabbit peroxidase-antiperoxidase complex (PAP, (Dako)
diluted 1:400 in PBS) for 45 min at room temperature. After
washing in PBS the sections were incubated twice for 15 min
with SAR and PAP. For DAB development, slides were
incubated for 5 min in 50 mM Tris-HCI, pH 7.5 containing
10 mM imidazole then for 5 min in the same medium contain-
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Figure 1 Western blot using anti-human rabbit antiserum: rH,
pure recombinant human ATase; L, human liver extract; M,
human melanoma extract; R, Raji cell extract; T, TK6 cell ex-
tract. The positions of the molecular weight marker proteins are
shown. See text for details.
ing 0.5 mg ml-' DAB and 3% hydrogen peroxide. Slides
were washed in water, dehydrated, mounted and photo-
graphed. For silver detection, after the second application of
PAP, the sections were washed in TBS then incubated at
room temperature for 5min in TBS containing nickel-
complexed DAB (0.5 mgml-' DAB in 80% TBS containing
10% aqueous (NiCl2.6H20). The sections were then incubated
in the above solution containing 10 yl of 30% hydrogen
peroxide for 5 min and the reaction stopped by three 1 min
washes in distilled water. This was followed by incubating in
silver reagent (prepared according to Przepiorka and Myer-
son, 1986, by mixing 400yII water with 200jil 0.1 M
ammonium nitrate, 200 ilI 0.047 M silver nitrate, 180 tlI
0.12M dodecatungstosilic acid (Fisons), 15fI 36% formalin
and 1 ml 0.47 M sodium carbonate). The slides were given
three 1 min washes in water, a 2 min wash in 2% sodium
thiosulphate and a 5 min wash in running tap water, de-
hydrated in alcohols, cleared in xylene and mounted in XAM
(BDH).
Results
Western blotting
The ATase specific activities in the crude sonicates of the
TK6 and RAJI cells were <2 fm mg-i and 400 fm mg-'
respectively. Western blotting revealed a heavily staining
band in the RAJI but not the TK6 extracts at ca. 24 kDa,
corresponding to the size of the pure recombinant human
ATase and the bands seen in crude extracts of human liver
and melanoma (Figure 1). An additional higher molecular
weight protein was faintly detected at around 48 kDa in both
of the cell extracts but not in the human tissue extracts or the
recombinant protein (Figure 1).
Immunostaining
In the present report, six liver and 16 melanoma samples
were assessed histopathologically for the inter and intra-
cellular distribution and intensity of staining. Using pre-
immune serum, faint cytoplasmic and nuclear staining were
seen such that in normal liver (Figures 2a and 3a) and
melanoma (Figures 4al and 4bl) tissue architecture was
easily discerned. In general, incubation with the ATase
antiserum showed very heavy nuclear staining although more
faint cytoplasmic staining was seen in some sections. The
results for two liver samples are shown in Figures 2 and 3
and for two melanoma samples in Figures 4a and 4b: the
corresponding haematoxylin and eosin staining is shown in
Figures 2c, 3c, 4a3 and 4b3.
In the liver sections there was relatively homogeneous and
intense staining of the hepatocytes and this was pre-
dominantly in the nucleus with little or no cytoplasmic stain
in most of the samples. The bile duct epithelial cells present-
ed a similar picture although cytoplasmic staining was also
seen in one of the samples. In most of the samples, the portal
vein endothelial cells and the Kuppfer cells were not stained.
There was no apparent predominance of centrilobular or
periportal staining in any of the sections.
In the melanoma sections, all cell types that could be
discerned, including melanoma cells, keratinocytes, endo-
thelial cells, fibroblasts and smooth muscle cells showed
staining that was predominantly nuclear. In some cases the
melanoma cell staining was heterogeneous and many of the
nuclei appeared free of stain (e.g. Figure 4a2). As with the
liver samples, there was interindividual variation in staining
intensity.
As further confirmation of the specificity of the antiserum,
liver sections serial to a sample showing marked antibody
staining were incubated with antigen-preincubated antiserum
then subjected to the standard protocol. The result (Figure
3c) was indistinguishable from that obtained with preimmune
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Fugwe 2 Staining of a normal human liver sample with (a) prammune .rum, (b) ATase antiserum and (c) haematoxylin and
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Fugwe 3 Staining of a normal human lver sample with: (a) preimmune serum (b) ATase antiserum, (c) antigen-preadsorbod
antiserum and (d) hacmatoxyin and eosin. Magnification x 230.
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Discussion
The antiserum we have produced is highly specific for the
human ATase detecting a strongly reacting 24 kDa band in
extracts of RAJI cells that expressed high levels of ATase but
not in TK6 cells that expressed almost undetectable levels of
this protein. Although the human cell extracts contained a
cross-reacting high molecular weight protein, this was not
seen in human tissue extracts and appeared not to be present
in the pure recombinant protein used as the immunogen. The
antiserum has also recently been shown to inhibit the human
but not rodent ATases in liquid hybridisation experiments
(Santibanez-Koref et al., 1992; Rafferty et al., 1992).
The antiserum readily detected endogenous expression of
the human ATase protein in sections of human liver and
melanoma and in- sections of human ATase-transgenic mice
(Fan et al., 1990; Fan et al., in preparation). In both cases
the staining appeared to be located predominantly over the
nucleus although some cytoplasmic staining was detected in
some samples. The specificity of the antiserum was further
confirmed by preadsorption of the antiserum with the pure
recombinant ATase protein after which staining was reduced
to the levels seen with preimmune serum.
There are several reports in which the intracellular dis-
tribution of ATase has been addressed using subcellular frac-
tionation procedures. The cytosolic fraction of rat liver was
reported to contain 35% (Jun et al., 1985), 59% (Pegg et al.,
1983) or 72% (Hora et al., 1983) of the total ATase activity.
Earlier indications were that rat liver nuclei contained 75%
of the total cellular enzyme (Renard & Verly, 1980). Since
the polyclonal antibodies used in the present work have not
so far detected the rat ATase in liver sections we are unable
to confirm these findings. In the present report, cytoplasmic
staining showed considerable intercellular and interindividual
variation in human liver and melanoma, but was in most
cases much less intense than in the nuclei. It may be that rat
and human tissues are very different in the cellular distribu-
tion of ATase but it might also be that cell fractionation
procedures disturb the true location of the protein. Alterna-
tively the antibodies may be better able to detect the human
ATase when it is located in the nucleus, in chromatin or
bound to DNA, rather than in the cytoplasm. Another ex-
planation is that the processing procedure used here might
effectively remove the enzyme from the cytoplasm or in some
other way render it undetectable. These possibilities are being
investigated.
In the liver, the hepatocytes and bile duct epithelial cells
were stained and whilst this staining was apparently relatively
uniform, in some of the samples there was no detectable
staining of the portal vein endothelial cells or Kuppfer cells.
This highly heterogeneous intercellular distribution of stain-
ing suggests that the ATase gene is not being transcribed and
translated at a level that can be detected in all of the liver
cells. In the rat liver, a degree of heterogeneity of repair of
06-methylguanine is likely to occur since hepatocytes lose
this lesion in a matter of hours whereas in endothelial cells
and fibroblasts the lesion is retained for much longer.
Indirect evidence of repair enzyme deficient cells has also
been observed in rat lung, kidney cortex and glandular
stomach (O'Connor et al., 1990). It may be possible to
confirm the heterogeneity of ATase staining by in situ hybrid-
isation using riboprobes on normal tissue sections or by
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Figure 4 Staining of two human malignant melanoma samples (a and b) with: (al and bl) preimmune serum, (a2 and b2) ATase
antiserum and (a3 and b3) haematoxylin and eosin. Note that in (a2), the epidermal keratinocytes show strong cytoplasmic and
nuclear staining whilst the melanoma cells show mainly nuclear staining. In (b3), melanoma cells show nuclear staining with
variation in intensity between cells. Vascular endothelial cell nuclei are also strongly stained. Magnification (a) x 180 (b)
x 200.
immunostaining using anti-06-methylguanine antibodies
(O'Connor et al., 1988) on tissue sections from patients
treated with methylating antitumour agents. The significance
in carcinogenesis of a heterogeneous cellular distribution of
ATase remains to be established, however it is tempting to
speculate that higher levels of expression might provide
greater protection against the carcinogenic effect of environ-
mental and endogenously produced alkylating agents.
In some of the melanomas, there was a marked inter-
cellular heterogeneity in the staining of the melanoma cells.
The major clinical significance of this finding is that if ATase
is the principal mechanism of resistance to the toxic effects of
antitumour alkylating agents (D'Incalci et al., 1988; Pegg,
1990; Margison & O'Connor, 1990), it might be predicted
that whilst a portion of the cells would be killed (assuming
that they received a sufficiently high dose of the agent) there
would be a number of resistant cells in the population. It is
tempting to speculate that it would be these cells that would
continue to grow and be responsible for the re-emergence of
the disease, unless the numbers were reduced to below a level
at which immune surveillance would be effective. Indeed it
has been shown that in melanoma, resistance to DTIC or its
metabolite MTIC develops rapidly in vivo (Clark, 1976) and
in vitro (Parsons et al., 1982) and in the latter case not by
decreased uptake of the drug but via enhanced repair of
methylation damage in DNA (Parsons et al., 1982; Hayward
& Parsons, 1984; Maynard et al., 1988; Foster et al., 1990).
An extensive study is now required in order to establish
whether or not there is a correlation between ATase levels in
tumour extracts, the number of ATase positively staining
cells and the intensity of staining, the response of the tumour
to treatment and the frequency of relapse. A large number of
tumour types will also need to be examined in order, even-
tually, to assess whether or not alkylating agent treatment
would be appropriate for any individual patient.
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